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In this issue of Cancer Cell, Andersen et al. report on a small molecule that interacts with and blocks trans-
activation of the androgen receptor amino-terminal domain. This agent can overcome the shortcomings of
clinically used antiandrogens, an important advance in the development of effective therapy for advanced
prostate cancer.Experimental androgen-deprivation ther-
apy (ADT) for prostate cancer in the form
of estrogen treatment or surgical castra-
tion was first reported nearly 70 years
ago (Huggins and Hodges, 1941). The
results of these initial studies were trans-
lated to the clinic, where ADT was shown
to retard the inexorable progression of
prostate cancer. Subsequent research
yielded significant improvements in ADT
through the development ofmore effective
pharmacologicagents, including inhibitors
of androgen-synthetic pathways, that are
currently being tested in clinical trials (Vis
and Schroder, 2009). The relative success
of ADT and the exquisite sensitivity of the
prostate and prostate cancer to andro-
gens have sustained the androgen axis,
and particularly the androgen receptor
(AR), as the premier therapeutic target for
prostate cancer. An early approach to
improving ADT by using AR targeting was
the development of competing androgen
antagonists (bicalutamide, flutamide) that
interact with the carboxyl-terminal ligand-
binding domain (LBD) of the AR.
Unfortunately, however, the develop-
ment of so-called castrate-resistant pros-
tate cancer (CRPC) limits the effects of
ADT. CRPC is believed to emerge after
genetic and/or epigenetic changes in
prostate cancer cells render them insensi-
tive to ADT. CRPC is characterized partly
by overexpression of AR (Taplin and Balk,
2004). In addition, the use of antiandro-
gens that target the LBD can lead to selec-
tion of prostate cancer cells that harbor AR
mutations in theLBD. Insomecases, these
mutations can cause prostate cancer cells
to acquire the capacity to convert thoseantiandrogens from antagonists to ago-
nists (Chen et al., 2008; Steinkamp
et al., 2009). Recently, a second-genera-
tion antiandrogen was built on the chemi-
cal scaffold of the nonsteroidal agonist
RU59063, which also interacts with the
AR LBD (Van Dort et al., 2000). This thera-
peutic agent, MDV3100, has notable
advantageous biologic properties, in-
cluding increased affinity of the AR;
suppression of AR nuclear translocation,
DNA binding, and coactivator recruitment;
proapoptotic activities; and lack of detect-
able agonistic effects (Tran et al., 2009).
However, CRPC can also exhibit ligand-
independentARactivation throughvarious
signaling pathways (Chen et al., 2008; Vis
and Schroder, 2009). Further, CRPC can
express AR-splicing variants that lack the
carboxyl terminus, including the LBD (Na-
cusi and Tindall, 2009; Vis and Schroder,
2009). These activities could provide a
means of escape from the effects of
agents that target the AR LBD.
The report byAndersenetal. in this issue
of Cancer Cell shows that EPI-001, which
is a BADGE (Bisphenol A Diglycidic Ether)
analog, may have the potential to over-
come the ‘‘Achilles’ heel’’ of the antiandro-
gens that target the AR LBD (Andersen
et al., 2010). The authors present impres-
sive results demonstrating that EPI-001
interacts with the activation function
(AF)-1 region in the amino-terminal domain
(NTD) of the AR anddoes not interfere with
ligand binding. Additionally, EPI-001 does
not inhibit the transcriptional activity of
progesterone receptor or glucocorticoid
receptor. These results suggest that EPI-
001 is specific to the AR without inhibitingCancer Cellthe transcriptional activities of other
steroid receptors. These unique proper-
ties, elegantly demonstrated by Andersen
and colleagues, may partly explain the
lack of any significant toxicity associated
with administration of EPI-001 in preclin-
ical animal studies. They further under-
score that resistance to EPI-001 through
mutations in the LBD is not likely to occur
via any known mechanism(s).
The results showing that EPI-001
blocks the AR amino-carboxyl terminal
(N/C) interactions, and protein-protein
interactions with the AR provide a molec-
ular mechanism through which EPI-001
inhibits both androgen-dependent and,
importantly, selective androgen-indepen-
dent AR transactivation. It is interesting
that many, but not all, androgen-regu-
lated genes were inhibited by EPI-001,
suggesting that the molecular constraints
imposed on the AR by EPI-001 translate
into a unique inhibitory gene profile. In
turn, this suggests that additional experi-
ments to define the downstream genetic
pathways suppressed by EPI-001 may
reveal new therapeutic targets.
Andersen and colleagues also show
that EPI-001 can block transactivation of
a constitutively active AR deletion mutant
containing theNTD,DNA-binding domain,
and hinge region, but not the LBD. In light
of recent data that show CRPC expresses
such AR mutants (Nacusi and Tindall,
2009; Vis andSchroder, 2009), it is difficult
to overstate the importance of this capac-
ity of EPI-001.
Preclinical results using subcutaneous
and orthotopic xenograft models showed
that EPI-001 can effectively block both17, June 15, 2010 ª2010 Elsevier Inc. 525
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Figure 1. Potential of EPI-001 to Inhibit Specific Aberrant Androgen Receptor
Transactivation Activities that Contribute to Castrate-Resistant Prostate Cancer
(A) On the basis of its interaction with the AF-1 region of the AR amino-terminal domain (NTD), EPI-001
would not be expected to reduce the selection pressure for AR amplification and/or mutations in the
AR NTD that are associated with CRPC. However, because EPI-001 does not interact with the ligand-
binding domain (LBD) or reduce ligand binding, it is unlikely that treatment would impose selection for
gain-of-function LBDmutations that allow for AR-mediated activities in the presence of reduced or altered
ligands.
(B) EPI-001 can block forskolin (FSK)- or IL-6-mediated ligand-independent AR transactivation activities.
(C) EPI-001 can inhibit a constitutively active AR deletion mutant that lacks the LBD. P, possible AR phos-
phorylation sites; filled rectangles, proteins that interact with AR to promote FSK- or IL-6–mediated ligand-
independent AR transactivation; DBD, DNA-binding domain; AF-1, activation function-1; AF-2, activation
function-2. AR protein domains are not drawn to scale.
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cancer growth. Additional experiments
showed that EPI-001 can also significantly
reduce the weight of the prostate in intact
male mice. Of considerable importance is
that no significant toxicity was observed.
Overall, these impressive results strongly
support the therapeutic potential of EPI-
001 or its derivatives in vivo.
The novel mechanism of action (interac-
tion with the AR NTD) through which EPI-
001 inhibits AR transactivation suggests
uniqueadvantagesofEPI-001 for inhibiting
CRPC. First, EPI-001’s capacity to interact
with and inhibit AR function without affect-
ing the LBDdefines a new level of pharma-
cologic specificity, which may suppress
selection pressure for mutations in the AR
LBD that allow CRPC to become resistant
to currently used antiandrogens (Figure 1).
However, previous investigators have sug-
gested a relationship between AR overex-
pression and altered normal responses to
AR antagonists (Chen et al., 2008). Further
testing of EPI-001 or its derivatives for the
development of gain-of-function muta-
tions in the AR LBD will likely clarify this
important question.526 Cancer Cell 17, June 15, 2010 ª2010 ElsSecond, EPI-001’s capacity to inhibit
the ligand-independent AR transactivation
mediated by forskolin (FSK), which stimu-
lates PKA activity, or IL-6 breaks new
ground in the pharmacologic suppression
of AR (Figure 1). Certainly, themechanisms
underlying ligand-independent AR trans-
activationarepoorlydefined. In this regard,
it is important that the authors demon-
strated that EPI-001 inhibited interactions
between AR-AF-1 and CBP or RAP74 and
inhibited N/C interactions through its inter-
action with the NTD AF-1. Although these
results have important therapeutic implica-
tions, other mechanisms of ligand-inde-
pendent AR transactivation may permit an
escape from EPI-001’s effects. Additional
studies to analyze EPI-001’s capacity to
inhibit pathways of ligand-independent
AR transactivation other than FSK and
IL-6 that lead to CRPC will be necessary
to address this issue and perhaps lead to
important information related to AR struc-
ture-activity relationships.
Third, recent reports of the expression of
AR splicing variants lacking the carboxyl
terminus, including the LBD, reveal a new
mechanism of antiandrogen resistanceevier Inc.and represent a considerable threat to the
efficacy of currently used antiandrogens.
EPI-001’s capacity to block transactivation
of a constitutively active AR deletion
mutant that contains the NTD, the DNA-
binding domain, and the hinge region, but
not the LBD, is a unique and critical func-
tion that will, we hope, have a substantial
effect in CRPC. Further studies that test
additionalARdeletionmutants that contain
the NTD, but not other AR domains, will
generate a more comprehensive picture
of this important and unique activity of
EPI-001.
CRPC is biologically complex and
certainly presents new and unforeseen
difficulties in the medical management of
advanced prostate cancer. The molecular
and cellular interactions that contribute to
prostate cancer growth, and its resistance
to ADT and antiandrogen therapy within
the bonemicroenvironment are just begin-
ning to be understood.However, it is a rare
occasion in prostate cancer research
when such a unique and promising thera-
peutic agent for advancedprostate cancer
is developed. We all wait with interest the
further preclinical and possible clinical
testing of EPI-001 or its derivative(s).
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